Descripción de la empresa
DNA X, Inc. operates within the Technology sector, specifically serving the Software - Infrastructure industry by providing enterprise 5G solutions across the United States, Canada, Europe, the Middle East, and the Asia Pacific. The company's core business involves supplying ruggedized cell phones designed for task workers, including specific models such as the Sonim XP10, Sonim XP5plus, Sonim XP3plus, Sonim XP Pro, XP100 4G, and XP400 5G professional rugged phones. According to available data, the company maintains a market capitalization of $5.03M, generates $59.11M in annual revenue over the trailing twelve months, and employs a workforce of 131 individuals. These valuation figures indicate that DNA X, Inc. is a micro-cap entity with a relatively small market presence compared to large-cap technology peers, suggesting a niche position focused on specialized industrial hardware rather than broad consumer electronics markets.
Salud financiera
The financial performance of DNA X, Inc. is characterized by a trailing twelve-month revenue of $59.11M, a net income loss of $-33,384,000, and an EBITDA of $-28,269,000. The substantial gap between the $59.11M revenue and the $-33,384,000 net income reveals a significant cost structure burden, where operating expenses and taxes exceed gross profits to the point of generating a negative profit margin of -56.5%. Additionally, the company reported a gross margin of 17.9% and an operating margin of -24.5%, which indicates that while the company retains a portion of revenue after the cost of goods sold, it fails to cover its operating overheads effectively. In terms of liquidity, the company holds $2.14M in cash against $5.07M in debt, resulting in a debt-to-equity ratio listed as N/A due to the negative equity position. The current ratio stands at 0.78, indicating that the company's current assets are insufficient to cover its current liabilities without external financing or asset liquidation. Furthermore, the return on equity is -455.8% and the return on assets is -44.3%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets held during this period. Finally, the free cash flow is reported at $-12,125,375, highlighting a lack of financial flexibility as the company consumes cash to fund its operations and growth initiatives.
Evaluación de valoración
Valuation metrics for DNA X, Inc. present a complex picture where the P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is 4.02. The difference between a non-existent trailing multiple and a forward multiple of 4.02 implies that the market is pricing in future earnings recovery rather than current profitability, suggesting an expectation of a trajectory toward positive net income in the coming fiscal periods. The price-to-book ratio is -4.90, which indicates that the stock trades at a significant discount relative to its book value, a common characteristic for companies with substantial accumulated losses or negative equity. Alternative valuation measures include a price-to-sales ratio of 0.09 and an EV/EBITDA of -0.23, suggesting that investors are valuing the company primarily on its sales volume rather than profitability or cash flow generation. Regarding price volatility, the 52-week high is $38.52 and the 52-week low is $2.52. Without a specific current price provided in the source data to calculate the exact percentage deviation, the trading range demonstrates extreme historical volatility within a span of over 1,400%. The beta value is 1.72, which means the stock price is expected to be 72% more volatile than the broader market, presenting higher risk for price fluctuations relative to standard market indices.
Growth & Income
The growth profile of DNA X, Inc. shows a revenue growth of 7.9% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. Since earnings growth is not applicable in a negative income scenario, the company is currently growing top-line sales without yet achieving corresponding earnings expansion, which implies that profitability is not yet being realized from this revenue increase. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all available earnings or utilizes cash reserves to fund operations and capital expenditures rather than distributing income to shareholders. The overall growth and income profile suggests a high-risk, high-potential-reward scenario typical of early-stage technology hardware firms that prioritize market share expansion and product development over immediate income generation or shareholder returns.